INFORMAZIONI SU QUESTO PODCAST 🔗

Frequenza di aggiornamento:
every 21 days
Durata media dell'audio:
9 minutes
Interviste agli ospiti
Inglese
Stati Uniti
212 episodi
da 02 Agosto 2017
episodic

ULTIMO EPISODIO 🔗

The FAME 3 Trial

William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.

CERCA TRA GLI EPISODI PASSATI

Cerca gli episodi passati di Talking Points.

EPISODI PRECEDENTI

Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.

The PROCTOR Trial

Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.

The META-AF Trial

Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da TCTMD, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.